Welcome!

News Feed Item

Critical Outcome Technologies Inc. Reports Fiscal 2013 Second Quarter Financial Results

LONDON, ONTARIO -- (Marketwire) -- 12/21/12 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced fiscal 2013 second quarter financial results today for the three and six months ended October 31, 2012.

"As we have outlined in the past, the Company has a two-pronged strategy for commercial validation of its underlying CHEMSAS® technology," said Dr. Wayne Danter, President and Chief Executive Officer. "The first strategy is to license a novel compound discovered and optimized using CHEMSAS® that has been successfully moved through preclinical testing as predicted. The second strategy is to enter into research and product development (R&D) collaboration agreements with third parties for therapeutic targets of interest to them. Both of these strategies progressed very well in the quarter."

"We continued our COTI-2 licensing initiatives during the quarter on a number of fronts, which included the engagement of a life science commercialization consulting firm to broaden the Company's reach, experience and effort with the licensing transaction. We believe the positive progress being made in both the scientific results for COTI-2 and our R&D collaboration programs highlighted below will provide momentum for success in this initiative," said Dr. Wayne Danter.

"While only modest revenue was received during the quarter under the collaboration agreements announced in September 2012, we are building shareholder value through the revenue "tails" of milestone payments and royalties that ensue from successfully completing these discovery, optimization and profiling collaborations," noted Dr. Danter. "These collaborations also expand the number and types of parties that can benefit from using CHEMSAS®, which is important in demonstrating the breadth and depth of CHEMSAS® as a drug discovery engine."

Financial Highlights

The Company reported a net loss of $762,669 or $0.01 per common share for the three months ended October 31, 2012 (Q2-F'13) compared to a net loss of $648,530 or $0.01 per common share for the comparable quarter ended October 31, 2011 (Q2-F'12). For the six months ended October 31, 2012 (YTD-F'13) the Company reported a net loss of $1,485,439 or $0.02 per common share compared to a net loss of $1,290,786 or $0.02 per common share for the six months ended October 31, 2011. The increased loss in the quarter of $114,139 and $194,653 for the six month period related to two major functional expense areas; R&D expenses increased by $113,453 in the quarter and $174,507 year to date and general and administration (G&A) expenses increased by $13,866 for the quarter and $39,270 year to date.

The R&D increase related primarily to R&D testing, consulting and materials, which increased $96,636 in the quarter (YTD-F'13 - $218,615) due to increased in vitro and in vivo testing of the Company's lead oncology asset, COTI-2. This increase was partially offset by a decrease in synthesis costs of $7,601 in the quarter (YTD-F'13 - $84,880).

The G&A increase related to two expense items; first, Q2-F'13 amortization costs increased by $11,901 (YTD-F'13 - $22,816) resulting from the grant of a patent for COTI-2 by the United States Patent Office in October 2011; and, second, share-based compensation increased $40,152 (YTD-F'13 - $41,356) due to share options granted to officers and a consultant. These increases were partially offset by a reduction in professional fees in the quarter of $31,294 (YTD-F'13 - $18,218) as the Company did not incur the consulting service fees associated with the required transition to International Financial Reporting Standards of 2012.

At the quarter end, the Company held cash, cash equivalents and short-term investments of $575,530. This balance reflected a decline of $1,143,141 since the April 30, 2012 year end with cash used in operating activities representing $1,166,047. "The Company is pursuing additional financing to sustain operations and execute on its business plan with an anticipated closing in the first quarter of calendar 2013," advised Dr. Danter.

Operational Highlights

The Company made steady progress in developing COTI-2 toward an investigational new drug filing leading to human clinical trials and a licensing transaction in the quarter. On September 18, 2012, the Company announced the initiation of the final series of toxicity experiments in two animal species using the oral formulation. On September 20, 2012, the Company announced the broadening of the mechanism of action (MOA) of COTI-2 beyond AKT inhibition. Previous preclinical MOA work clearly showed that COTI-2 modulated the PI3K/AKT/mTOR pathway. However, new data derived from gene profiling and in vitro testing indicates that COTI-2 is particularly effective in treating cancer cell lines with p53 mutations, an effect not associated with AKT inhibitors. "The effectiveness of COTI-2 based on the status of p53, a tumor suppressing gene, could make this compound and class an important new treatment for cancer, as at least 50% of human cancers harbor a p53 mutation. These findings improved the understanding of COTI-2's MOA and help clarify some of the positive results seen in earlier experiments and trials that were not explained by AKT inhibition alone," stated Dr. Danter.

Efforts in achieving R&D collaborations using the Company's proprietary CHEMSAS® platform with a variety of life science organizations culminated in the Company being able to announce two collaborations in the quarter; one with Western University on September 6, 2012 and another with Delmar Chemicals Inc. on September 12, 2012. Subsequent to the quarter end, the Company announced a third collaboration on December 6 with a multinational pharmaceutical company. "Success with these collaborations provides important commercial validation of CHEMSAS®, a source of revenue to the Company and illustrates the capability of the platform to function across multiple disease areas," noted Dr. Danter.

More detailed operating and financial results can be found in the Company's unaudited condensed interim financial statements and the Management Discussion and Analysis for the three and six months ended October 31, 2012, which can both be found on SEDAR at www.sedar.com. This material is also available on the Company's website at www.criticaloutcome.com.

Notice to Readers

Information provided in this press release may contain certain statements which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement "Success with these collaborations provides important commercial validation of CHEMSAS®, a source of revenue to the Company and illustrates the capability of the platform to function across multiple disease areas..." and "could make this compound and class an important new treatment for cancer..." and "... pursuing additional financing to sustain operations and execute on its business plan with an anticipated closing in the first quarter of calendar 2013..." are forward-looking statements. These statements convey the Company's efforts to commercially validate CHEMSAS® and file a submission to enable human clinical trials to occur for its lead oncology compound and also efforts to obtain a licensing deal and financing, but COTI is not in a position at this time to determine when, or if these events will occur. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. Risks that could impact on these forward-looking statements are outlined in the Company's annual information form. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements.

About Critical Outcome Technologies Inc.

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective. Upon confirming the predictions of CHEMSAS® through a series of preclinical tests, COTI seeks to license these compounds for further preclinical and clinical compounds.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
As pervasive as cloud technology is -- and as persuasive as the arguments are for using it -- the cloud has its limits. Some companies will always have security concerns about storing data in the cloud and certain high-transaction applications will always be better suited for on-premises storage. Those statements were among the bottom-line takeaways delivered at Cloud Expo this week, a three day, bi-annual event focused on cloud technologies, adoption and associated challenges.
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...